"Does insurance cover peptides?" has a short answer and a useful long one. The short answer: insurance covers some approved peptide drugs, for their approved uses, usually after prior authorization; it rarely covers compounded peptides; and it cannot cover products sold for research use. The long answer is about what decides coverage — the drug's legal status, the purpose it is prescribed for, and a set of federal exclusions that remove whole categories of use.
This page excludes the GLP-1 drugs (semaglutide, tirzepatide and others), which have their own coverage rules and fights; GLP1 Ledger covers them in its GLP-1 insurance coverage guide. What peptides cost without coverage is on our peptide cost page. Nothing here is legal or benefits advice; a plan's own documents decide any individual case.
The three categories
| Category | Examples | Can a plan cover it? | What usually happens |
|---|---|---|---|
| FDA-approved peptide drug, approved use | Tesamorelin (HIV abdominal fat), teriparatide (osteoporosis), octreotide, bremelanotide | Yes, if on the formulary | Prior authorization with diagnosis, measurements and prescriber requirements |
| Approved drug, non-approved use | Tesamorelin for general belly fat | Sometimes, by exception | Usually denied as not medically necessary |
| Compounded peptide (pharmacy-made) | Sermorelin, compounded peptides under 503A | Rarely | Paid out of pocket |
| Research-use-only product | BPC-157, TB-500, MOTS-c sold "not for human use" | No | Not a drug for people; nothing to cover |
Approved peptides are listed on our FDA-approved peptides page. How pharmacy compounding works, and which peptides it can use, is on our 503A vs 503B page. What "research use only" means legally is on our research-use-only explainer.
The federal exclusions that remove whole uses
Two federal statutes do much of the deciding for public plans, and commercial formularies often follow similar lines.
Medicaid. Under 42 U.S.C. 1396r-8(d)(2) (read 14 October 2026), states may exclude or restrict coverage of drugs, or their uses, in named classes, including:
- agents when used for anorexia, weight loss or weight gain;
- agents when used to promote fertility;
- agents when used for cosmetic purposes or hair growth;
- agents when used for sexual or erectile dysfunction, unless approved for another condition.
Medicare Part D. The definition of a covered Part D drug in 42 U.S.C. 1395w-102(e)(2) excludes the drugs and uses on that Medicaid list, with exceptions for smoking-cessation agents and, in defined cases, barbiturates and benzodiazepines. The weight-loss, fertility, cosmetic and sexual-dysfunction exclusions therefore apply to Part D.
The exclusions attach to the use, not the molecule. That is why the same approved drug can be covered for one purpose and excluded for another, and why so much of what peptide clinics offer — body composition, ageing, libido, skin — falls inside an excluded or non-approved use even when the molecule is approved for something else. Medicare Part B separately covers injectable drugs for postmenopausal osteoporosis supplied by a home health agency, under conditions set out in 42 U.S.C. 1395x(kk).
What a prior authorization looks like: tesamorelin in 2026
Tesamorelin is the clearest worked example, because it is an approved peptide whose label is narrow and whose name is often attached to a broad use (belly fat). Two current policies we read set out the terms.
Nevada Medicaid (CareSource, effective 1 January 2026) — policy PDF, read 14 October 2026:
| Requirement | Initial approval |
|---|---|
| Age | 18 or older |
| Prescriber | Infectious-disease specialist or endocrinologist, or in consultation |
| Diagnosis | HIV-associated lipodystrophy with excess visceral abdominal fat |
| Measurements, men | Waist > 95 cm and waist-to-hip ratio > 0.94 |
| Measurements, women | Waist > 94 cm and waist-to-hip ratio > 0.88 |
| Treatment history | Stable antiretroviral treatment for at least 8 weeks |
| Attestations | Not for simple obesity or weight loss; no active malignancy |
| Quantity limit | 30 vials per 30 days (SV) or 4 vials per 28 days (WR) |
| Approval length | 6 months; renewal for 12 months only if chart notes show visceral fat has fallen (CT, waist or waist-to-hip) |
The policy states that CareSource considers tesamorelin not medically necessary for any condition it does not list. Cigna's prior-authorization policy for the same drugs (review date 20 May 2026) also requires a specialist prescriber, repeats the label's limits — not indicated for weight loss, long-term cardiovascular safety not established — and advises weighing whether to continue in patients without a clear response at the week-26 assessment.
Two features generalise to other approved peptides. The thresholds are the trial's entry criteria: the waist and waist-to-hip cut-offs are the ones the pivotal trials enrolled on, which our tesamorelin results page sets out. And renewal depends on a measured response, not on how a patient feels — the plan wants the same evidence the trial used.
Why compounded and research peptides fall outside
Compounded peptides are prepared by a pharmacy for an individual prescription rather than approved as products. They are not approved products, so they do not appear on a formulary the way an approved drug does; whether a plan pays for one is set by that plan's own documents. Sermorelin is the common example: its only approved product, Geref, was discontinued, so what remains is compounded supply, normally paid out of pocket. Our sermorelin results page covers its history. NAD+ injections, which have no approved label at all, show what fully self-pay pricing looks like on our dated NAD injection cost survey.
Research-use-only products — the large market in BPC-157, TB-500, MOTS-c and similar peptides — are sold labelled "not for human consumption." They are not drugs prescribed for a person, so there is no claim a plan could pay.
How to check a specific case
- Find the plan's policy document by drug name. Most insurers publish prior-authorization criteria; the policy, not a clinic's summary, is what decides.
- Compare the stated use with the label. A use outside the approved indication is the most common reason for denial.
- Check whether a federal exclusion applies — weight loss, fertility, cosmetic or sexual-dysfunction uses in Medicare Part D and, where the state has chosen it, Medicaid.
- Expect measured renewal criteria. Plans that cover approved peptides tend to ask for the trial's measure of response before renewing.
Out-of-pocket prices for the approved and compounded options are compared on our peptide cost page.